Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Risankizumab

😃Good
Catalog No. T76778Cas No. 1612838-76-2
Alias SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Risankizumab

Risankizumab

😃Good
Catalog No. T76778Alias SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066Cas No. 1612838-76-2
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$243In StockIn Stock
5 mg$793-In Stock
10 mg$1,230-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95.3% (SDS-PAGE); 98.3% (SEC-HPLC)
Contact us for more batch information

Product Introduction

Bioactivity
Description
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Targets&IC50
IL-17:17 pM (cynomolgus), IL-17:2 pM (human), IL-23:10pM (kd,human), IL-23:10pM (kd,cynomolgus)
In vitro
With Kds <10 pM, Risankizumab (BI 655066) exhibits high affinity for human and cynomolgus IL23[3]. Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[2].
In vivo
In mice, Risankizumab (BI 655066) inhibits IL23-induced ear swelling and cytokine production following a single intraperitoneal (i.p.) dosage of 1 mg/kg[2].
SynonymsSKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIL-23a
Chemical Properties
Molecular Weight145.85 kDa
Cas No.1612838-76-2
ColorTransparent
AppearanceLiquid
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Risankizumab | purchase Risankizumab | Risankizumab cost | order Risankizumab | Risankizumab chemical structure | Risankizumab in vivo | Risankizumab in vitro | Risankizumab molecular weight